|1.||Fujii, Nobutaka: 12 articles (09/2010 - 03/2002)|
|2.||Tamamura, Hirokazu: 11 articles (01/2009 - 03/2002)|
|3.||Tamamura, H: 7 articles (11/2001 - 12/2000)|
|4.||Hiramatsu, Kenichi: 6 articles (01/2007 - 03/2002)|
|5.||Nakashima, Hideki: 6 articles (06/2006 - 03/2002)|
|6.||Fujii, N: 6 articles (08/2001 - 12/2000)|
|7.||Nakashima, H: 6 articles (08/2001 - 12/2000)|
|8.||Oishi, Shinya: 5 articles (09/2010 - 03/2002)|
|9.||Yamamoto, Naoki: 5 articles (06/2006 - 03/2002)|
|10.||Kanamoto, T: 5 articles (08/2001 - 12/2000)|
01/01/2008 - "There were positive trends in the incidences of adenoma or carcinoma (combined) in the pars distalis of the pituitary gland of females in the F(1)C and F(1)T140 arms, and the incidence in the 500 ppm group was significantly greater than that in the controls in the F(1)C study arm. "
01/01/2008 - "In 5 and 100 ppm F(1)T140 females, the combined incidences of adenoma and adenocarcinoma were less than those in the control or 500 ppm groups, although these were not statistically significant differences. "
01/01/2009 - "Here, we examined the efficacy of T140 analogs, TF14016 and TF14013, on the inhibition of FIV infection. "
01/01/2004 - "Based on the hypothesis that the HIV-1 viruses were carrying heterogeneity of functional and nonfunctional gp120 and required the formation of sufficient multiple-site binding of functional gp120 with receptors to proceed to infection, viruses with many functional gp120 which were infectious at RT and infectious to cells with reduced numbers of CXCR4 by T140 treatment were resistant to 0.5beta. "
01/01/2004 - "Increased temperature enhances the infectivity of human immunodeficiency virus type 1 (HIV-1), and this enhancement is inhibited by anti-CXCR4 peptide T140, implying that multiple-site binding is required to proceed to infection. "
12/01/2005 - "The authors developed selective CXCR4 antagonists, T22 and T140, initially as anti-HIV agents, which inhibit T cell line-tropic (X4-) HIV-1 infection through their specific binding to CXCR4. "
02/01/2003 - "A highly selective CXCR4 antagonist, T22, and its downsized analogues T140 and TC14012, which inhibit X4-HIV-1 infection through their specific binding to CXCR4, have been identified. "
08/01/2009 - "The unique ability of the CXCR4 antagonist, T140 to stimulate the production and exit of WBC cells may be used as a novel therapeutic approach to overcome cytopenia associated with treatments for cancer and BM transplantation."
01/01/2008 - "Under the conditions of this 2-year feed study with exposure to the test compound from conception through 20 weeks followed by control feed until termination (F(1)T140), there was no evidence of carcinogenic activity of genistein in male Sprague-Dawley rats exposed to 5, 100, or 500 ppm. There was equivocal evidence of carcinogenic activity of genistein in female Sprague-Dawley rats based on marginally increased incidences of pituitary gland neoplasms. "
07/02/2004 - "Analogs of the 14-mer peptide T140 were previously found to be specific CXCR4 antagonists that were characterized as not only HIV-entry inhibitors but also anti-cancer-metastatic agents. "
06/21/2006 - "A linear type of several low molecular weight CXCR4 antagonists were developed based on T140 analogs, which were previously found to be strong CXCR4 antagonists that block X4-HIV-1 entry and have inhibitory activities against cancer metastasis/progression and rheumatoid arthritis."
01/01/2009 - "CXCR4 antagonists, such as Plerixafor (AMD3100) and T140 analogs, can disrupt adhesive tumor-stroma interactions and mobilize leukemia cells from their protective stromal microenvironment, making them more accessible to conventional drugs. "
|5.||Body Weight (Weight, Body)
|2.||CXCR4 Receptors (CXCR4 Receptor)
|6.||HIV Fusion Inhibitors
|1.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)